Skip to main content
OpenTrials

Clinical trial condition

Post-essential Thrombocythemia Myelofibrosis

Explore clinical trials studying Post-essential Thrombocythemia Myelofibrosis. Study availability and eligibility vary by location and protocol.

27 public trials 9 recruiting studies
Refine in advanced search Browse all conditions

Post-essential Thrombocythemia Myelofibrosis trial results

Recruiting

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

NCT05320198

Conditions
Anemia, Bone Marrow Diseases, Hematologic Diseases, +8 more
Locations
  • Banner MD Anderson Gilbert, Arizona, United States
  • City of Hope - Duarte Duarte, California, United States
  • City of Hope - Lennar Irvine, California, United States
  • University of California, San Francisco San Francisco, California, United States
View all 28 locations
View Trial Details
Recruiting

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

NCT07469891

Conditions
Bone Marrow Diseases, Bone Marrow Neoplasms, Hematologic Diseases, +13 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • BRCR Global - Coral Springs Coral Springs, Florida, United States
  • START Midwest, LLC Grand Rapids, Michigan, United States
  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office Philadelphia, Pennsylvania, United States
View Trial Details
Recruiting

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

NCT06343805

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations
  • Stanford Cancer Institute Palo Alto, California, United States
  • Moffitt Cancer Cancer Center Tampa, Florida, United States
  • University of Kansas Medical Center Kansas City, Kansas, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
View all 21 locations
View Trial Details
Recruiting

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

NCT06351631

Conditions
Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, +15 more
Locations
  • University of Michigan ( Site 6000) Ann Arbor, Michigan, United States
  • DUHS Duke Blood Cancer Center ( Site 6005) Durham, North Carolina, United States
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007) Columbus, Ohio, United States
  • UPMC Hillman Cancer Center ( Site 6004) Pittsburgh, Pennsylvania, United States
View all 21 locations
View Trial Details

Related conditions